Takeda Looks To Ride 'Wave 1' To JPY5tn Target
12 NMEs Set For Mid-Term Launch
Executive Summary
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
You may also be interested in...
Takeda Stresses Orexin Commitment Despite Setback
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.
Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.
Takeda Sees Another Wave 1 Plan Come Crashing Down
The Phase III failure for pevonedistat in three rare blood cancer settings is the third setback for Takeda’s Wave 1 pipeline candidates this year. The NEDD8 inhibitor is still being studied in other settings.